Entrada Therapeutics, Inc. - TRDA STOCK NEWS

Entrada Therapeutics (Nasdaq: TRDA) recently announced that its President and CEO, Dipal Doshi, will participate in the Neuromuscular and Bone Corporate Panel at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston, MA. The conference aims to discuss advancements in healthcare, particularly in biotechnology. A live webcast of the panel will be accessible on Entrada's Investor Relations website, with a replay available for 90 days post-event. Entrada specializes in Endosomal Escape Vehicle (EEV™) therapeutics, targeting previously inaccessible diseases, with a focus on neuromuscular disorders.

Entrada Therapeutics (Nasdaq: TRDA) has announced the successful closing of its strategic collaboration with Vertex following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The agreement includes a $224 million upfront payment and a $26 million equity investment. Entrada could earn up to $485 million in milestone payments and royalties on future product sales. The collaboration focuses on ENTR-701, a candidate for treating myotonic dystrophy type 1 (DM1), and extends the company’s cash runway into the second half of 2025, enabling further development of its Endosomal Escape Vehicle (EEV™)-therapeutics.

Entrada Therapeutics announces the selection of ENTR-601-45 as a new clinical candidate for treating individuals with Duchenne muscular dystrophy who are amenable to exon 45 skipping. The biopharmaceutical company plans to submit an Investigational New Drug (IND) application in the second half of 2024. Initial studies demonstrate over 90% exon skipping in a hDMD mouse model. The company aims to address a significant unmet need in the Duchenne community and will present further data at the Muscular Dystrophy Association Clinical Conference in March 2023.

Entrada Therapeutics, Inc. (Nasdaq: TRDA) announced a clinical hold from the FDA on its IND application for ENTR-601-44, aimed at treating Duchenne muscular dystrophy. The FDA's formal Clinical Hold letter will be issued within 30 days. CEO Dipal Doshi expressed disappointment but is committed to addressing the FDA's concerns. The hold is significant as there are currently no approved therapies for patients with exon 44 skippable mutations in Duchenne. Further updates will follow as Entrada engages with the FDA.

Vertex Pharmaceuticals (VRTX) and Entrada Therapeutics (TRDA) have announced a global collaboration to develop intracellular EEV therapeutics for myotonic dystrophy type 1 (DM1). Entrada will receive an upfront payment of $224 million along with $26 million in equity and is eligible for future milestone payments totaling up to $485 million. The collaboration focuses on Entrada’s late-stage preclinical candidate, ENTR-701, which aims to address underlying causes of DM1. Vertex will lead further development, manufacturing, and commercialization efforts.

Entrada Therapeutics (Nasdaq: TRDA) announced that CEO Dipal Doshi will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual Conference on November 29, 2022, at 3:55 PM ET. This event highlights Entrada's commitment to revolutionizing medicine through its Endosomal Escape Vehicle (EEV^TM) therapeutics, targeting previously inaccessible intracellular diseases. The chat will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days post-event.

Entrada Therapeutics (Nasdaq: TRDA) reported financial results for Q3 2022, with a net loss of $25.1 million compared to $14.4 million in Q3 2021. As of September 30, 2022, the company had $216 million in cash and equivalents, projected to fund operations into 2H 2024. The company is on track to submit an IND for ENTR-601-44 for Duchenne muscular dystrophy by Q4 2022 and plans to initiate a single ascending dose study in 2023. R&D expenses rose to $19 million from $10.5 million a year prior, driven by increased preclinical study investments.

Entrada Therapeutics (Nasdaq: TRDA) announced that Nathan Dowden, Chief Operating Officer, will virtually present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be accessible starting September 12, 2022, at 7:00 a.m. Eastern Time on the company's website. A replay will be available for 90 days after the event. Entrada focuses on Endosomal Escape Vehicle (EEV™) therapeutics for treating diseases including Duchenne muscular dystrophy and myotonic dystrophy.

Entrada Therapeutics (Nasdaq: TRDA) announced that it is on track to submit an Investigational New Drug (IND) application for ENTR-601-44, targeting Duchenne muscular dystrophy (DMD), in Q4 2022. The company holds $244 million in cash and equivalents, ensuring a cash runway into 2H 2024. R&D expenses surged to $16.2 million from $6.8 million year-over-year, with a net loss of $23.2 million for Q2 2022. Entrada also presented promising preclinical data for its therapeutic candidates and initiated collaborations aimed at accelerating developments in neuromuscular disease treatments.